116 results on '"Owen, Andrew"'
Search Results
2. Prospects for Long-Acting Treatments for Hepatitis C.
- Author
-
Thomas, David L, Owen, Andrew, and Kiser, Jennifer J
- Subjects
- *
DRUG efficacy , *ORAL drug administration , *HEPATITIS C , *ANTIVIRAL agents , *PATIENTS' attitudes , *TREATMENT effectiveness , *DECISION making in clinical medicine - Abstract
In 2019, more than 4 years after the widespread availability of safe, oral, curative treatments, an estimated 58 million people were living with hepatitis C virus infections (PLWHC). Additional tools may enable those not yet reached to be treated. One such tool could be long-acting parenteral formulations of HCV treatments, which may allow PLWHC to be diagnosed and cured in a single encounter. Although existing highly effective oral medications might be formulated as long-acting parenteral treatments, pharmacological, regulatory, patent, and medical challenges have to be overcome; this requires the concerted efforts of PLWHC, researchers, funding agencies, industry, the World Health Organization, and other stakeholders. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm.
- Author
-
Neary, Megan, Owen, Andrew, and Olagunju, Adeniyi
- Subjects
- *
HIV infections , *DRUG delivery systems , *IN vitro studies , *BIOLOGICAL models , *DRUG efficacy , *SMALL molecules , *CLINICAL drug trials , *ANTI-infective agents , *MONOCLONAL antibodies , *TISSUE engineering , *PHARMACEUTICAL chemistry , *DRUG development - Abstract
Lack of predictive preclinical models is a key contributor to the steep attrition rate in drug development. Successful clinical translation may be higher for new chemical entities or existing approved drugs reformulated for long-acting (LA) administration if preclinical studies designed to identify any new uncertainties are predictive of human exposure and response. In this review, we present an overview of standard preclinical assessments deployed for LA formulations and delivery systems, using human immunodeficiency virus LA therapeutics preclinical development as a paradigm. Key progress in the preclinical development of novel LA antiretrovirals formulations and delivery systems are summarized, including bispecific broadly neutralizing monoclonal antibody and small molecule technologies for codelivery of multiple drugs with disparate solubility properties. There are new opportunities to take advantage of recent developments in tissue engineering and 3-dimensional in vitro modeling to advance preclinical modeling of anti-infective activity, developmental and reproductive toxicity assessment, and to apply quantitative modeling and simulation strategies. These developments are likely to drive the progression of more LA anti-infective drugs and multipurpose technologies into clinical development in the coming years. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases.
- Author
-
Flexner, Charles, Siccardi, Marco, Bunglawala, Fazila, and Owen, Andrew
- Subjects
DRUG therapy for tuberculosis ,HIV infections ,COMMUNICABLE diseases ,EVALUATION of human services programs ,CLINICAL drug trials ,MATHEMATICAL models ,ANTIRETROVIRAL agents ,HEPATITIS ,CONTROLLED release preparations ,QUALITY assurance ,COMMUNICATION ,THEORY ,PHARMACEUTICAL chemistry ,DRUG development ,PHARMACEUTICAL industry - Abstract
Developing long-acting products and formulations for infectious diseases is a nontrivial undertaking that is frequently classified as high risk and low reward by the pharmaceutical industry. The Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP) was founded in 2015 with the support of the National Institutes of Health to encourage, promote, and accelerate the development of such products. Assessment methodology for any new proposal brought to this group is part of a framework—the LEAP Process—that includes a landscape analysis of what is currently available in the public domain. This is followed by in silico modeling and simulation offered as a service to the relevant scientific community. A variety of preclinical and clinical outcome metrics are applied to each new agent as part of a continuous feedback loop to improve product characteristics. This allows us to catalog knowledge gaps and barriers that can be addressed by engaged stakeholders. Results are communicated in scientific articles, reviews, and position papers. This undertaking serves to de-risk discovery, development, and implementation by bridging the gaps between academic, regulatory, and industrial investigators, and by engaging those in the community who will be the eventual users of these medicines. The LEAP Process has supported formulations now approved for human immunodeficiency virus, as well as products in clinical and preclinical development for tuberculosis and hepatitis viruses B and C. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment.
- Author
-
Ammerman, Nicole C, Nuermberger, Eric L, Owen, Andrew, Rannard, Steve P, Meyers, Caren Freel, and Swindells, Susan
- Subjects
TUBERCULOSIS prevention ,DRUG delivery systems ,CLINICAL drug trials ,PUBLIC health ,PREVENTIVE health services ,ANTITUBERCULAR agents ,DRUG development ,PHARMACEUTICAL chemistry - Abstract
A key component of global tuberculosis (TB) control is the treatment of latent TB infection. The use of long-acting technologies to administer TB preventive treatment has the potential to significantly improve the delivery and impact of this important public health intervention. For example, an ideal long-acting treatment could consist of a single dose that could be administered in the clinic (ie, a "1-shot cure" for latent TB). Interest in long-acting formulations for TB preventive therapy has gained considerable traction in recent years. This article presents an overview of the specific considerations and current preclinical advancements relevant for the development of long-acting technologies of TB drugs for treatment of latent infection, including attributes of target product profiles, suitability of drugs for long-acting formulations, ongoing research efforts, and translation to clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. PDGFRα/Sca-1 Sorted Mesenchymal Stromal Cells Reduce Liver Injury in Murine Models of Hepatic Ischemia-Reperfusion Injury.
- Author
-
Owen, Andrew, Patten, Daniel, Vigneswara, Vasanthy, Frampton, Jon, and Newsome, Philip N
- Subjects
LIVER cells ,STROMAL cells ,REPERFUSION injury ,LIVER injuries ,LIVER transplantation ,REPERFUSION - Abstract
Liver transplantation is an effective therapy, but increasing demand for donor organs has led to the use of marginal donor organs with increased complication rates. Mesenchymal stromal cells (MSC) pleiotropically modulate aberrant immune-mediated responses and represent a potential therapy to target the inflammation seen post-transplant with marginal donor livers. To avoid the confounding effects of xenotransplantation seen in studies with human MSC, a PDGFRα/Sca-1 (PaS) sorted MSC population was used which was analogous to human MSC populations (LNGFR
+ Thy-1+ VCAM-1Hi ). PaS MSC are a well-described population that demonstrate MSC properties without evidence of clonal mutation during expansion. We demonstrate their anti-inflammatory properties herein through their suppression of T-lymphocyte proliferation in vitro and secretion of anti-inflammatory cytokines (IL-10 and OPG) after stimulation (P =.004 and P =.003). The MDR2−/− model of biliary injury and hepatic ischemia-reperfusion (HIR) injury models were used to replicate the non-anastomotic biliary complications seen following liver transplantation. Systemic MSC therapy in MDR2−/− mice led to reduced liver injury with an increase in restorative macrophages (5913 ± 333.9 vs 12 597 ± 665.8, P =.002, n = 7) and a change in lymphocyte ratios (3.55 ± 0.37 vs 2.59 ± 0.139, P =.023, n = 17), whereas subcutaneous administration of MSC showed no beneficial effect. MSC also reduced cell death in the HIR model assessed by Periodic acid–Schiff (PAS) staining (91.7% ± 2.8 vs 80.1% ± 4.6, P =.03). Systemically administered quantum dot-labeled MSC were tracked using single-cell resolution CryoViz imaging which demonstrated their sequestration in the lungs alongside retention/redistribution to injured liver tissue. MSC represent a potential novel therapy in marginal organ transplantation which warrants further study. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
- Author
-
Sokhela, Simiso, Bosch, Bronwyn, Hill, Andrew, Simmons, Bryony, Woods, Joana, Johnstone, Hilary, Akpomiemie, Godspower, Ellis, Leah, Owen, Andrew, Casas, Carmen Perez, and Venter, Willem Daniel Francois
- Abstract
Background: The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the risk of SARS-CoV-2 infection. Nitazoxanide was selected given its favourable pharmacokinetics and in vitro antiviral effects against SARS-CoV-2. Sofosbuvir/daclatasvir had shown favourable results in early clinical trials.Methods: In this clinical trial in Johannesburg, South Africa, healthcare workers and others at high risk of infection were randomized to 24 weeks of either nitazoxanide or sofosbuvir/daclatasvir as prevention, or standard prevention advice only. Participants were evaluated every 4 weeks for COVID-19 symptoms and had antibody and PCR testing. The primary endpoint was positive SARS-CoV-2 PCR and/or serology ≥7 days after randomization, regardless of symptoms. A Poisson regression model was used to estimate the incidence rate ratios of confirmed SARS-CoV-2 between each experimental arm and control.Results: Between December 2020 and January 2022, 828 participants were enrolled. COVID-19 infections were confirmed in 100 participants on nitazoxanide (2234 per 1000 person-years; 95% CI 1837-2718), 87 on sofosbuvir/daclatasvir (2125 per 1000 person-years; 95% CI 1722-2622) and 111 in the control arm (1849 per 1000 person-years; 95% CI 1535-2227). There were no significant differences in the primary endpoint between the treatment arms, and the results met the criteria for futility. In the safety analysis, the frequency of grade 3 or 4 adverse events was low and similar across arms.Conclusions: In this randomized trial, nitazoxanide and sofosbuvir/daclatasvir had no significant preventative effect on infection with SARS-CoV-2 among healthcare workers and others at high risk of infection. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments.
- Author
-
Weld, Ethel D, Astemborski, Jacqueline, Kirk, Gregory D, Sulkowski, Mark S, Katz, Stephanie, Rothman, Richard, Solomon, Sunil S, Matthews, Gail V, Hsieh, Yu Hsiang, Verma, Malvika, Traverso, Giovanni, Swindells, Susan, Owen, Andrew, Feld, Jordan, Flexner, Charles, Mehta, Shruti H, and Thomas, David L
- Subjects
HEPATITIS C treatment ,HEPATITIS C risk factors ,DRUG delivery systems ,CROSS-sectional method ,PATIENTS' attitudes ,DESCRIPTIVE statistics - Abstract
Background Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment. Methods A cross-sectional, 43-question survey was administered to 1457 individuals with or at risk of HCV at 28 sites in 9 countries to assess comparative interest in a variety of long-acting strategies in comparison with oral pills. Results Among HCV-positive participants, 37.7% most preferred an injection, 5.6% an implant, and 6% a gastric residence device, as compared with 50.8% who stated they would most prefer taking 1–3 pills per day. When compared directly to taking pills, differences were observed in the relative preference for an injection based on age (P <.001), location (P <.001), and prior receipt of HCV treatment (P =.005) but not sex. When an implant was compared with pills, greater preference was represented by women (P =.01) and adults of younger ages (P =.01 per 5 years). Among participants without HCV, 49.5% believed that injections are stronger than pills and 34.7% preferred taking injections to pills. Among those at-risk participants who had received injectable medications in the past, 123 of 137 (89.8%) expressed willingness to receive one in the future. Conclusions These data point to high acceptability of long-acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Controlling trapping, overgrazing and invasive vegetation is key to saving Java's last population of the Black-winged Myna.
- Author
-
Squires, Thomas M., Collar, Nigel J., Devenish, Christian, Owen, Andrew, Pratiwi, Arif, Winarni, Nurul L., and Marsden, Stuart J.
- Subjects
OVERGRAZING ,ACRIDOTHERES cristatellus ,HABITATS ,SPECIES distribution ,CATTLE - Abstract
Copyright of Ornithological Applications is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
10. Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?
- Author
-
Hiscox, Julian A., Khoo, Saye H., Stewart, James P., and Owen, Andrew
- Subjects
SARS-CoV-2 ,DRUG target ,COVID-19 treatment ,DRUG resistance ,DRUG development ,INFLUENZA viruses ,ANTIVIRAL agents ,INFLUENZA - Abstract
This article provides a brief overview of drug resistance to antiviral therapy as well as known and emergent variability in key SARS-CoV-2 viral sequences. The purpose is to stimulate deliberation about the need to consider drug resistance prior to widespread roll-out of antivirals for SARS-CoV-2. Many existing candidate agents have mechanisms of action involving drug targets likely to be critical for future drug development. Resistance emerged quickly with monotherapies deployed for other pulmonary viruses such as influenza virus, and in HIV mutations in key drug targets compromised efficacy of multiple drugs within a class. The potential for drug resistance in SARS-CoV-2 has not yet been rigorously debated or assessed, and we call for more academic and industry research on this potentially important future threat prior to widespread roll-out of monotherapies for COVID-19 treatment and prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
- Author
-
Pertinez, Henry, Rajoli, Rajith K R, Khoo, Saye H, and Owen, Andrew
- Subjects
SARS-CoV-2 ,DRUG dosage ,CONCENTRATION functions ,CHINESE people ,MATHEMATICAL models ,LATENT structure analysis - Abstract
Objectives: Favipiravir has discrepant activity against SARS-CoV-2 in vitro, concerns about teratogenicity and pill burden, and an unknown optimal dose. This analysis used available data to simulate the intracellular pharmacokinetics of the favipiravir active metabolite [favipiravir ribofuranosyl-5'-triphosphate (FAVI-RTP)].Methods: Published in vitro data for intracellular production and elimination of FAVI-RTP in Madin-Darby canine kidney cells were fitted with a mathematical model describing the time course of intracellular FAVI-RTP as a function of favipiravir concentration. Parameter estimates were then combined with a published population pharmacokinetic model in Chinese patients to predict human intracellular FAVI-RTP. In vitro FAVI-RTP data were adequately described as a function of concentrations with an empirical model, noting simplification and consolidation of various processes and several assumptions.Results: Parameter estimates from fittings to in vitro data predict a flatter dynamic range of peak to trough for intracellular FAVI-RTP (peak to trough ratio of ∼1 to 1) when driven by a predicted free plasma concentration profile, compared with the plasma profile of parent favipiravir (ratio of ∼2 to 1). This approach has important assumptions, but indicates that, despite rapid clearance of the parent from plasma, sufficient intracellular FAVI-RTP may be maintained across the dosing interval because of its long intracellular half-life.Conclusions: Population mean intracellular FAVI-RTP concentrations are estimated to be maintained above the Km for the SARS-CoV-2 polymerase for 9 days with a 1200 mg twice-daily regimen (following a 1600 mg twice-daily loading dose on day 1). Further evaluation of favipiravir as part of antiviral combinations for SARS-CoV-2 is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Back to the Future: Democratic Responsiveness and the Estimation of Future Public Opinion.
- Author
-
Merkley, Eric and Owen, Andrew
- Subjects
- *
PUBLIC opinion , *GOVERNMENT policy - Abstract
Research on the responsiveness of policy to public opinion has infrequently confronted the possibility that re-election seeking politicians' policy choices may reflect their expectations about future public opinion. This article reports observational and experimental findings from a survey of senior Canadian policy-makers. Results from vignette-based experiments that manipulate the characteristics of current and estimates of future opinion show that policy-makers are responsive to the estimated direction of future opinion, but this relationship is conditional on high estimated future salience. Survey results shed additional light on the role that estimates of future opinion play in policy-making. Combined, these experimental and observational results suggest existing empirical work on policy responsiveness is incomplete. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.
- Author
-
Elliot, Emilie R, Neary, Megan, Else, Laura, Khoo, Saye, Moyle, Graeme, Carr, Daniel F, Wang, Xinzhu, Mcclure, Myra, Boffito, Marta, and Owen, Andrew
- Subjects
PYRIDINE ,PROTEINS ,RESEARCH ,HETEROCYCLIC compounds ,RESEARCH methodology ,GENETIC polymorphisms ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies - Abstract
Objectives: Dolutegravir has replaced efavirenz as first-line treatment in universal HIV guidelines. We sought to ascertain the contributory effect of SNPs in four key genes linked to dolutegravir disposition (UGT1A1, ABCG2, CYP3A and NR1I2) on plasma dolutegravir pharmacokinetics.Methods: Paired pharmacogenetic/pharmacokinetic data from 93 subjects were analysed for association using multivariate linear regression.Results: Co-occurring UGT1*28 and NR1I2 c.63396C>T homozygosity was associated with a 79% increase in AUC0-24 (P = 0.001; 27% if analysed individually), whilst combined ABCG2 c.421C>A and NR1I2 c.63396C>T variants were associated with a 43% increase in Cmax (P = 0.002) and a 39% increase in AUC0-24 (P = 0.002). When analysed individually, homozygosity for the NR1I2 c.63396C>T variant alleles was associated with a 28% increase in Cmax (P = 0.033) and homozygosity for the ABCG2 c.421C>A variant alleles was associated with a 28% increase in Cmax (P = 0.047). The UGT1A1*28 (rs8175347) poor metabolizer status (*28/*28; *28/*37; *37/*37) was individually associated with a 27% increase in AUC0-24 (P = 0.020). The combination of UGT1A1*28 poor metabolizer and UGT1A1*6 intermediate metabolizer statuses correlated with a 43% increase in AUC0-24 (P = 0.023).Conclusions: This study showed a pharmacogenetic association between dolutegravir pharmacokinetics and variants in the ABCG2, UGT1A1 and NR1I2 genes, particularly when combined. Further research is warranted to confirm these associations in population-specific studies and to investigate their putative relationship with dolutegravir pharmacodynamics. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
- Author
-
Bunglawala, Fazila, Rajoli, Rajith K R, Mirochnick, Mark, Owen, Andrew, and Siccardi, Marco
- Subjects
HIV infection transmission ,NEWBORN infants ,FORECASTING ,PHARMACOKINETICS ,EXPOSURE therapy ,HIV infections ,PYRIDINE ,RESEARCH ,HIV integrase inhibitors ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies - Abstract
Background: Only a few antiretroviral drugs (ARVs) are recommended for use during the neonatal period and there is a need for more to be approved to increase treatment and prophylaxis strategies. Dolutegravir, a selective integrase inhibitor, has potential for treatment of HIV infection and prophylaxis of transmission in neonates.Objectives: To model the pharmacokinetics of dolutegravir in neonates and to simulate a theoretical optimal dosing regimen.Methods: The physiologically based pharmacokinetic (PBPK) model was built incorporating the age-related changes observed in neonates. Virtual neonates between 0 and 28 days were simulated. The model was validated against observed clinical data for raltegravir and midazolam in neonates, prior to the prediction of dolutegravir pharmacokinetics.Results: Both raltegravir and midazolam passed the criteria for model qualification, with simulated data within 1.8-fold of clinical data. The qualified model predicted the pharmacokinetics for several multidose regimens of dolutegravir. Regimen 6 involved 5 mg doses with a 48 h interval from Day 1-20, increasing to 5 mg once daily on Week 3, yielding AUC and Ctrough values of 37.2 mg·h/L and 1.3 mg/L, respectively. These exposures are consistent with those observed in paediatric patients receiving dolutegravir.Conclusions: Dolutegravir pharmacokinetics were successfully simulated in the neonatal PBPK model. The predictions suggest that during the first 3 weeks of life a 5 mg dose administered every 48 h may achieve plasma exposures needed for therapy and prophylaxis. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
- Author
-
Dickinson, Laura, Gurjar, Rohan, Stöhr, Wolfgang, Bonora, Stefano, Owen, Andrew, D'Avolio, Antonio, Cursley, Adam, Molina, Jean-Michel, Fäetkenheuer, Gerd, Vandekerckhove, Linos, Perri, Giovanni Di, Pozniak, Anton, Richert, Laura, Raffi, François, Boffito, Marta, Group, NEAT001/ANRS143 Study, Di Perri, Giovanni, and NEAT001/ANRS143 Study Group
- Subjects
RALTEGRAVIR ,PHARMACOGENOMICS ,GLYCOPYRROLATE ,PHARMACOKINETICS ,GENETIC polymorphisms ,ANTI-HIV agents ,HIV infections ,RESEARCH ,VIRAL load ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RITONAVIR - Abstract
Objectives: NEAT001/ANRS143 demonstrated non-inferiority of once-daily darunavir/ritonavir (800/100 mg) + twice-daily raltegravir (400 mg) versus darunavir/ritonavir + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily) in treatment-naive patients. We investigated the population pharmacokinetics of darunavir, ritonavir, tenofovir and emtricitabine and relationships with demographics, genetic polymorphisms and virological failure.Methods: Non-linear mixed-effects models (NONMEM v. 7.3) were applied to determine pharmacokinetic parameters and assess demographic covariates and relationships with SNPs (SLCO3A1, SLCO1B1, NR1I2, NR1I3, CYP3A5*3, CYP3A4*22, ABCC2, ABCC10, ABCG2 and SCL47A1). The relationship between model-predicted darunavir AUC0-24 and C24 with time to virological failure was evaluated by Cox regression.Results: Of 805 enrolled, 716, 720, 347 and 361 were included in the darunavir, ritonavir, tenofovir and emtricitabine models, respectively (11% female, 83% Caucasian). No significant effect of patient demographics or SNPs was observed for darunavir or tenofovir apparent oral clearance (CL/F); coadministration of raltegravir did not influence darunavir or ritonavir CL/F. Ritonavir CL/F decreased by 23% in NR1I2 63396C>T carriers and emtricitabine CL/F was linearly associated with creatinine clearance (P<0.001). No significant relationship was demonstrated between darunavir AUC0-24 or C24 and time to virological failure [HR (95% CI): 2.28 (0.53-9.80), P=0.269; and 1.82 (0.61-5.41), P=0.279, respectively].Conclusions: Darunavir concentrations were unaltered in the presence of raltegravir and not associated with virological failure. Polymorphisms investigated had little impact on study-drug pharmacokinetics. Darunavir/ritonavir + raltegravir may be an appropriate option for patients experiencing NRTI-associated toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.
- Author
-
Ayuso, Pedro, Neary, Megan, Chiong, Justin, and Owen, Andrew
- Subjects
HOMOZYGOSITY ,ANDROSTANE receptors ,META-analysis ,METABOLISM ,GENETIC code ,EFAVIRENZ - Abstract
Background Efavirenz primary metabolism is catalysed by CYP2B6 with minor involvement of CYP2A6. Subsequently, phase I metabolites are conjugated by UGT2B7, and constitutive androstane receptor (CAR) has been shown to transcriptionally regulate many relevant enzymes and transporters. Several polymorphisms occurring in the genes coding for these proteins have been shown to impact efavirenz pharmacokinetics in some but not all studies. Objectives A meta-analysis was performed to assess the overall effect of CYP2B6 rs3745274, CYP2A6 (rs28399454, rs8192726 and rs28399433), UGT2B7 (rs28365062 and rs7439366) and NR1I3 (rs2307424 and rs3003596) polymorphisms on mid-dose efavirenz plasma concentrations. Methods Following a literature review, pharmacokinetic parameters were compiled and a meta-analysis for these variants was performed using Review Manager and OpenMetaAnalyst. A total of 28 studies were included. Results Unsurprisingly, the analysis confirmed that individuals homozygous for the T allele for CYP2B6 rs3745274 had significantly higher efavirenz concentrations than those homozygous for the G allele [weighted standard mean difference (WSMD) = 2.98; 95% CI 2.19–3.76; P < 0.00001]. A subgroup analysis confirmed ethnic differences in frequency but with a similar effect size in each ethnic group (P = 0.96). Associations with CYP2A6 and UGT2B7 variants were not statistically significant, but T homozygosity for CAR rs2307424 was associated with significantly lower efavirenz concentrations than in C homozygotes (WSMD = −0.32; 95% CI −0.59 to −0.06; P = 0.02). Conclusions This meta-analysis provides the overall effect size for the impact of CYP2B6 rs3745274 and NR1I3 rs2307424 on efavirenz pharmacokinetics. The analysis also indicates that some previous associations were not significant when interrogated across studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Polymetry and Metaphysics in F. T. Prince.
- Author
-
Owen, Andrew Wynn
- Subjects
- *
LITERARY criticism , *POETRY (Literary form) , *AESTHETICS , *POETS - Abstract
A literary criticism of the book "Reading F. T. Prince" by Will May is presented. It is the most distinctive voices of twentieth-century anglophone poetry. It outlines poet to have been an admirably coherent and rigorous aesthetic thinker, an artist whose intricate technical dedication forged a deep compact with his interest in labour, physicality, vulnerability, matter and mind.
- Published
- 2019
- Full Text
- View/download PDF
18. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
- Author
-
Neary, Megan, Chappell, Catherine A, Scarsi, Kimberly K, Nakalema, Shadia, Matovu, Joshua, Achilles, Sharon L, Chen, Beatrice A, Siccardi, Marco, Owen, Andrew, and Lamorde, Mohammed
- Subjects
EFAVIRENZ ,GENETICS ,PHARMACOKINETICS ,DRUG metabolism ,SINGLE nucleotide polymorphisms - Abstract
Background: We previously demonstrated that etonogestrel concentrations were 82% lower in women using etonogestrel contraceptive implants plus efavirenz-based ART compared with women not receiving ART.Objectives: To investigate the genetic contribution to this previously observed drug-drug interaction through studying SNPs in genes known to be involved in efavirenz, nevirapine or etonogestrel metabolism in the same group of women.Patients and Methods: Here, we present a secondary analysis evaluating SNPs involved in efavirenz, nevirapine and etonogestrel metabolism and associated etonogestrel pharmacokinetics among 57 women, 19 not receiving ART (control group), 19 receiving efavirenz- (600 mg daily) based ART and 19 receiving nevirapine- (200 mg twice daily) based ART. Associations between patient genotype and etonogestrel pharmacokinetic parameters were determined through univariate and multivariate linear regression. This study was registered at clinicaltrials.gov (NCT02082652).Results: Within the control group, CYP2B6 983 T>C was associated with 27% higher etonogestrel Cmax and 28% higher AUC0-24weeks. In the efavirenz group CYP2B6 516 G>T was associated with 43% lower etonogestrel Cmin and 34% lower AUC0-24weeks. For participants receiving nevirapine, NR1I2 63396 C>T was associated with 39% lower etonogestrel Cmin and 37% lower AUC0-24weeks.Conclusions: This study demonstrates the influence of pharmacogenetics on the extent of drug-drug interactions between etonogestrel and efavirenz- or nevirapine-based ART. Efavirenz plus the etonogestrel contraceptive implant results in a detrimental drug-drug interaction irrespective of patient genetics, which is worsened in women possessing variant alleles for these CYP2B6 SNPs. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
- Author
-
Cerrone, Maddalena, Alfarisi, Omamah, Neary, Megan, Marzinke, Mark A, Parsons, Teresa L, Owen, Andrew, Maartens, Gary, Pozniak, Anton, Flexner, Charles, and Boffito, Marta
- Subjects
TENOFOVIR ,PHARMACOKINETICS ,RIFAMPIN ,EMTRICITABINE ,GENETIC polymorphisms - Abstract
Objectives: Tenofovir alafenamide produces lower plasma tenofovir and higher intracellular tenofovir diphosphate (DP) concentrations than tenofovir disoproxil fumarate but it is likely a victim of interactions with rifampicin. We aimed to investigate the pharmacokinetics of tenofovir alafenamide/emtricitabine with rifampicin.Patients and Methods: Healthy volunteers received tenofovir alafenamide/emtricitabine at 25/200 mg once daily, followed by tenofovir alafenamide/emtricitabine + rifampicin daily followed by tenofovir disoproxil fumarate. Plasma tenofovir alafenamide, tenofovir, emtricitabine and intracellular tenofovir-DP and emtricitabine triphosphate pharmacokinetics and genetic polymorphisms were assessed.Results: Tenofovir alafenamide exposure decreased when tenofovir alafenamide/emtricitabine + rifampicin was used compared with tenofovir alafenamide/emtricitabine [geometric mean ratio (GMR) (90% CI): 0.45 (0.33-0.60)]. Plasma tenofovir and intracellular tenofovir-DP concentrations decreased with rifampicin [GMR (90% CI): 0.46 (0.40-0.52) and 0.64 (0.54-0.75), respectively]. GMR (90% CI) of intracellular tenofovir-DP AUC0-24 for tenofovir alafenamide/emtricitabine + rifampicin versus tenofovir disoproxil fumarate was 4.21 (2.98-5.95). Rifampicin did not affect emtricitabine pharmacokinetics. CYP3A4*22 rs35599367 was associated with higher plasma tenofovir alafenamide AUC0-24 at day 56.Conclusions: Following tenofovir alafenamide/emtricitabine administration with rifampicin, intracellular tenofovir-DP concentrations were still 4.21-fold higher than those achieved by tenofovir disoproxil fumarate, supporting further study during HIV/TB co-infection. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.
- Author
-
Rajoli, Rajith K R, Curley, Paul, Chiong, Justin, Back, David, Flexner, Charles, Owen, Andrew, and Siccardi, Marco
- Subjects
RIFAMPIN ,ANTIRETROVIRAL agents - Abstract
Background: Cabotegravir and rilpivirine are 2 long-acting (LA) antiretrovirals that can be administered intramuscularly; their interaction with rifampicin, a first-line antituberculosis agent, has not been investigated. The aim of this study was to simulate and predict drug-drug interactions (DDIs) between these LA antiretroviral agents and rifampicin using physiologically based pharmacokinetic (PBPK) modeling.Methods: The designed PBPK models were qualified (according to European Medicines Agency guidelines) against observed data for oral formulations of cabotegravir, rilpivirine, and rifampicin. Induction potential of rifampicin was also qualified by comparing the DDI between oral cabotegravir and oral rilpivirine with rifampicin. Qualified PBPK models were utilized for pharmacokinetic prediction of DDIs.Results: PBPK models predicted a reduction in both area under the curve (AUC0-28 days) and trough concentration (Ctrough, 28th day) of LA cabotegravir of 41%-46% for the first maintenance dose coadministered with 600 mg once-daily oral rifampicin. Rilpivirine concentrations were predicted to decrease by 82% for both AUC0-28 days and Ctrough, 28th day following the first maintenance dose when coadministered with rifampicin.Conclusions: The developed PBPK models predicted the theoretical effect of rifampicin on cabotegravir and rilpivirine LA intramuscular formulations. According to these simulations, it is likely that coadministration of rifampicin with these LA formulations will result in subtherapeutic concentrations of both drugs. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
21. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals.
- Author
-
Cerrone, Maddalena, Wang, Xinzhu, Neary, Megan, Weaver, Christine, Fedele, Serge, Day-Weber, Isaac, Owen, Andrew, Hill, Andrew, McClure, Myra, and Boffito, Marta
- Subjects
RIFAMPIN ,DRUG therapy for tuberculosis ,ISONIAZID ,COMBINATION drug therapy ,CLINICAL trials ,CONFIDENCE intervals ,GENETIC polymorphisms ,HIV infections ,VIRAL load ,HIGHLY active antiretroviral therapy ,ANTI-HIV agents ,DESCRIPTIVE statistics ,CYTOCHROME P-450 ,EFAVIRENZ ,THERAPEUTICS - Abstract
Background The World Health Organization recommends efavirenz 400 mg (EFV
400 ) as first-line antiretroviral therapy, with a disclaimer that no data with anti-tuberculosis (TB) treatment exist. Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure. Methods PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a viral load (VL) <50 copies/mL switched to TDF/FTC/EFV400 . Genetic polymorphisms and pharmacokinetic (PK) parameters of EFV400 without (PK1) and with INH/RIF following 4 (PK2) and 12 (PK3) weeks of coadministration were evaluated. Results Twenty-six PLWH were enrolled; 22 completed PK2. All maintained VL <50 copies/mL throughout the study. Geometric mean ratio (GMR) PK2/PK1 of EFV400 maximum plasma concentration (Cmax), area under the curve (AUC), and concentration at 24 hours postdose (C24h) were 0.91 (90% confidence interval [CI],.83–.99), 0.91 (90% CI,.79–1.05), and 0.85 (90% CI,.72–.99), respectively. GMRs (90% CI) of PK3/PK2 and PK3/PK1 Cmax, AUC, and C24h were 0.95 (.86–1.05) and 0.92 (.83–1.01), 0.88 (.75–1.03) and 0.84 (.75–.93), and 0.84 (.72–.99) and 0.75 (.62–.92), respectively. Eleven of 22 participants carried polymorphisms in the CYP2B6 gene associated with slow EFV metabolism. Conclusions INH/RIF coadministration was associated with limited changes in EFV400 AUC (<25%), and EFV400 concentrations were maintained within ranges of those measured in PLWH in the ENCORE-1 study, irrespective of CYP2B6 genotype. The coadministration of EFV400 with anti-TB treatment can be considered and this is being confirmed in PLWH with TB. Clinical Trials Registration NCT02832778. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
22. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
- Author
-
Elliot, Emilie R, Cerrone, Maddalena, Else, Laura, Amara, Alieu, Bisdomini, Elisa, Khoo, Saye, Owen, Andrew, and Boffito, Marta
- Subjects
PHARMACOKINETICS ,CLINICAL trials ,ANTIRETROVIRAL agents ,HIV infection prognosis ,HIV infection risk factors - Abstract
Background Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of HIV-1 infection. Methods This Phase I, open-label, 57 day, crossover, pharmacokinetic (PK) study, enrolled healthy volunteers aged 18–65 years, who were randomized to one of two groups. Group 1 received dolutegravir (50 mg) once daily for 14 days followed by a 7 day washout, then a 14 day dolutegravir/darunavir/cobicistat (DTG/DRV/COBI) once-daily co-administration period followed by a 7 day washout and finally a 14 day period of darunavir/cobicistat (800/150 mg) once daily. Group 2 followed the same sequence starting with darunavir/cobicistat and concluding with dolutegravir. Each group underwent intensive PK sampling over 24 h on day 14 of each drug period and DTG/DRV/COBI concentrations were measured using validated LC-MS/MS methods. Results Twenty participants completed all PK phases. Thirteen were female and median age and BMI were 33.5 years and 27 kg/m
2 . Dolutegravir geometric mean ratios (GMR, DTG/DRV/COBI versus dolutegravir alone) and 90% CI for Cmax , AUC0–24 and C24 were 1.01 (0.92–1.11), 0.95 (0.87–1.04) and 0.9 (0.8–1.0), respectively. Darunavir GMR (DRV/COBI/DTG versus darunavir/cobicistat alone) and 90% CI for Cmax , AUC0–24 and C24 were 0.90 (0.83–0.98), 0.93 (0.86–1.00) and 0.93 (0.78–1.11), respectively. No grade 3 or 4 adverse events or laboratory abnormalities were observed. Conclusions Concentrations of dolutegravir and darunavir, when boosted with cobicistat, decreased by <10% during co-administration, suggesting this combination can be prescribed safely in the treatment of HIV-1, with no adjustment to current guideline-recommended dosages. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
23. Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum.
- Author
-
Lamorde, Mohammed, Wang, Xinzhu, Neary, Megan, Bisdomini, Elisa, Nakalema, Shadia, Byakika-Kibwika, Pauline, Mukonzo, Jackson K, Khan, Waheed, Owen, Andrew, and McClure, Myra
- Subjects
CLINICAL trials ,CONFIDENCE intervals ,DRUG monitoring ,GENETIC polymorphisms ,HIV infections ,HIV-positive persons ,PHARMACOGENOMICS ,PUERPERIUM ,VIRAL load ,TREATMENT effectiveness ,EFAVIRENZ ,PHARMACODYNAMICS ,PREGNANCY ,THERAPEUTICS - Abstract
Background A clinical trial showed that efavirenz 400 mg once daily (EFV400) is as effective as the standard adult dose. World Health Organization recommends EFV400 as an alternative first-line agent, but data are lacking in the third trimester of pregnancy (TT). We investigated the pharmacokinetics, efficacy, and CYP2B6 pharmacogenetics in HIV-infected women (WLWH) on EFV400 during TT and post-partum (PP). Methods An open-label 2-center study (United Kingdom, Uganda) was conducted in WLWH receiving antiretroviral regimens containing efavirenz 600 mg, who had their efavirenz dose reduced to EFV400. Weekly therapeutic drug monitoring (TDM), steady-state pharmacokinetic profiles (TT and PP), safety, virological efficacy, and CYP2B6 polymorphisms at positions 516 (C > T) and 938 (T > C) were evaluated. Results Twenty-five WLWH of African origin were enrolled. All had viral loads <50 copies/mL at baseline, which were maintained throughout the study. No infant was HIV infected. No WLWH were withdrawn due to low EFV400 TDM results. Geometric mean ratios (TT/PP; 90% confidence interval) for EFV400 maximum observed plasma concentration, area under the curve, and plasma concentration measured 24 hours after the observed dose were 0.97 (.85–1.10), 0.87 (.76–.99), and 0.77 (.65–.91), respectively. Five of 25 WLWH were slow metabolizers. Conclusions Although EFV400 pharmacokinetic parameters were slightly lower for TT compared with PP values, efavirenz concentrations exceeded cutoff levels established by the study and those measured in antiretroviral-naive patients receiving EFV400 in ENCORE1. All subjects maintained a viral load <50 copies/mL, suggesting that EFV400 can be used in pregnant WLWH. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother--infant pairs.
- Author
-
Waitt, Catriona, Olagunju, Adeniyi, Nakalema, Shadia, Kyohaire, Isabella, Owen, Andrew, Lamorde, Mohammed, and Khoo, Saye
- Subjects
PHARMACOKINETICS ,EMTRICITABINE-tenofovir ,LAMIVUDINE ,INFANT care ,BREAST milk - Abstract
Background: Breast milk transfer of first-line ART from mother to infant is not fully understood. Objectives: To determine the concentrations of lamivudine, emtricitabine and tenofovir in maternal blood, breast milk and infant blood from breastfeeding mother-infant pairs. Methods: Intensive pharmacokinetic sampling of maternal dried blood spots (DBS), dried breast milk spots (DBMS) and infant DBS from 30 Ugandan and 29 Nigerian mothers receiving first-line ART and their infants was conducted. DBS and DBMS were collected pre-dose and at 5-6 timepoints up to 12 h following observed dosing. Infant DBS were sampled twice during this period. Lamivudine, emtricitabine and tenofovir were quantified using LC-MS/MS, with non-compartmental analysis to calculate key pharmacokinetic parameters. Results: Peak concentrations in breast milk from women taking lamivudine and emtricitabine occurred later than in plasma (4-8 h compared with 2 h for lamivudine and 2-4 h for emtricitabine). Consequently, the milk-to-plasma (M:P) ratio of lamivudine taken once daily was 0.95 (0.82-1.15) for AUC
0-12 , whereas for AUC12-20 this was 3.04 (2.87-4.16). Lamivudine was detectable in 36% (14/39) of infants [median 17.7 (16.3-22.7) ng/mL]. For 200 mg of emtricitabine once daily, the median M:P ratio was 3.01 (2.06-3.38). Three infants (19%) had measurable emtricitabine [median 18.5 (17.6-20.8) ng/mL]. For 300 mg of tenofovir once daily, the median M:P ratio was 0.015 (0-0.03) and no infant had measurable tenofovir concentrations. Conclusions: Emtricitabine and lamivudine accumulate in breast milk and were detected in breastfeeding infants. In contrast, tenofovir penetrates the breast milk to a small degree, but is undetectable in breastfeeding infants. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug--drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.
- Author
-
Roberts, Owain, Rajoli, Rajith K. R., Back, David J., Owen, Andrew, Darin, Kristin M., Fletcher, Courtney V., Lamorde, Mohammed, Scarsi, Kimberly K., and Siccardi, Marco
- Subjects
PHARMACOKINETICS ,DRUG dosage ,DRUG interactions ,LEVONORGESTREL ,EFAVIRENZ ,HIGHLY active antiretroviral therapy ,MATHEMATICAL models - Abstract
Background: HIV-positive women receiving efavirenz-based ART and levonorgestrel contraceptive implants are at risk of low levonorgestrel exposure and unintended pregnancy. Objectives: To investigate clinically applicable dose-adjustment strategies to overcome the known drug-drug interaction (DDI) between levonorgestrel and efavirenz, using a physiologically based pharmacokinetic (PBPK) modelling-based approach. Methods: A PBPK model was qualified against clinical data to predict levonorgestrel plasma concentrations when standard-dose (150 mg) levonorgestrel implants were administered alone (control group), as well as when standard-dose or increased-dose (300 mg) levonorgestrel implants were coadministered with either 600 or 400 mg of efavirenz. Results: No difference was seen between in vivo clinical and PBPK-model-simulated levonorgestrel plasma con-centrations (P> 0.05). Simulated levonorgestrel plasma concentrations were ~50% lower at 48 weeks postimplant-placement in virtual individuals receiving standard-dose levonorgestrel with either 600 or 400 mg of efavirenz compared with the control group (efavirenz:control geometric mean ratio = 0.42 and 0.49, respectively). Conversely, increased-dose levonorgestrel in combination with either 600 or 400 mg of efavirenz was sufficient to restore levonorgestrel concentrations to levels similar to those observed in the 150 mg levonorgestrel control group 48 weeks post-implant-placement (efavirenz:control geometric mean ratio = 0.86 and 1.03, respectively). Conclusions: These results suggest that the clinically significant DDI between efavirenz and levonorgestrel is likely to persist despite efavirenz dose reduction, whereas dose escalation of implantable levonorgestrel may represent a successful clinical strategy to circumvent efavirenz-levonorgestrel DDIs and will be of use to inform clinical trial design to assess coadministration of efavirenz and levonorgestrel implants. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.
- Author
-
Olagunju, Adeniyi, Schipani, Alessandro, Bolaji, Oluseye, Khoo, Saye, and Owen, Andrew
- Subjects
EFAVIRENZ ,MATERNAL health ,GENOTYPES ,PHARMACOKINETICS ,ANTIRETROVIRAL agents ,DRUG dosage ,THERAPEUTICS ,HIV prevention ,HIV infection transmission ,VERTICAL transmission (Communicable diseases) ,BLACK people ,HETEROCYCLIC compounds ,HIV infections ,OXIDOREDUCTASES ,ANTI-HIV agents ,PREVENTION - Abstract
Objectives: Lack of data on the pharmacokinetics of efavirenz in pregnant women at the 400 mg reduced dose currently prevents universal roll-out. Population pharmacokinetic modelling was used to explore pharmacokinetic endpoints at 200, 400 and 600 mg daily doses in pregnant women stratified by CYP2B6 metabolic status.Methods: The analysis was based on 252 plasma efavirenz concentrations from 77 pregnant women (77 sparse, 175 intensive) who received antiretroviral regimens containing 600 mg of efavirenz. The model was developed using NONMEM®. The effect of genetics was investigated and concentration-time courses at steady-state were simulated for individuals (n = 1000 each) classified as CYP2B6 slow, intermediate and fast metabolizers at 200, 400 and 600 mg daily doses.Results: At a 400 mg reduced dose, predicted mean (90% CI) mid-dose efavirenz concentration (C12) was 2.24 μg/mL (0.89-4.18) in pregnant women classified as slow metabolizers, compared with 0.87 μg/mL (0.34-1.64) in intermediate metabolizers and 0.78 μg/mL (0.30-1.47) in fast metabolizers. C12 was below the 0.47 μg/mL threshold determined within the ENCORE 1 trial in 10% at 400 mg, 4.6% at 600 mg and 3.4% with genotype-guided dosing. The 4.0 μg/mL toxicity threshold was exceeded in 4.6% at 400 mg, 13.5% at 600 mg and 5.2% with genotype-guided dosing.Conclusions: These data provide context for the ongoing debate about reduction in efavirenz dose to 400 mg during pregnancy and should be interpreted alongside the lower toxicity expected with the lower dose. Additional research is required to investigate genotype-guided dose reduction in pregnant women. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
- Author
-
Moltó, José, Rajoli, Rajith, Back, David, Valle, Marta, Miranda, Cristina, Owen, Andrew, Clotet, Bonaventura, and Siccardi, Marco
- Subjects
PHARMACOKINETICS ,DRUG interactions ,ANTIRETROVIRAL agents ,ANTINEOPLASTIC agents ,CYTOCHROME P-450 ,BIOLOGICAL models ,COMPUTER simulation ,HETEROCYCLIC compounds ,HIV infections ,ANTI-HIV agents - Abstract
Background: Co-administration of antineoplastics with ART is challenging due to potential drug-drug interactions (DDIs). However, trials specifically assessing such DDIs are lacking. Our objective was to simulate DDIs between the antineoplastics erlotinib and gefitinib with key antiretroviral drugs and to predict dose adjustments using a physiologically based pharmacokinetic (PBPK) model.Methods: In vitro data describing chemical properties and pharmacokinetic processes of each drug and their effect on cytochrome P450 isoforms were obtained from the literature. Plasma drug-concentration profiles were simulated in a virtual population of 50 individuals receiving erlotinib or gefitinib alone or with darunavir/ritonavir, efavirenz or etravirine. Simulated pharmacokinetic parameters and the magnitude of DDIs with probe drugs (midazolam, maraviroc) were compared with literature values. Erlotinib and gefitinib pharmacokinetics with and without antiretrovirals were compared and dose-adjustment strategies were evaluated.Results: Simulated parameters of each drug and the magnitude of DDIs with probe drugs were in agreement with reference values. Darunavir/ritonavir increased erlotinib and gefitinib exposure, while efavirenz and etravirine decreased erlotinib and gefitinib concentrations. Based on our predictions, dose-adjustment strategies may consist of once-daily dosing erlotinib at 25 mg and gefitinib at 125 mg with darunavir/ritonavir; or erlotinib at 200 mg and gefitinib at 375 mg with etravirine. The interaction with efavirenz was not overcome even after doubling erlotinib or gefitinib doses.Conclusions: PBPK models predicted the in vivo pharmacokinetics of erlotinib, gefitinib and the antiretrovirals darunavir/ritonavir, efavirenz and etravirine, and the DDIs between them. The simulated dose-adjustments may represent valuable strategies to optimize antineoplastic therapy in HIV-infected patients. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. Order and Disorder in the Ottava Rima of Shelley and Byron.
- Author
-
WYNN OWEN, ANDREW
- Subjects
- *
OTTAVA rimas - Abstract
The article offers the author's view on the disorder and order in poets Mary Shelley and George Gordon Byron's ottava rima. He mentions their poems "The Witch of Atlas" and "Don Juan" as well as their depiction as an Aurora Borealis and an obstinate center. An overview of their rhymes and stanzas is also presented.
- Published
- 2017
- Full Text
- View/download PDF
29. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.
- Author
-
Bienczak, Andrzej, Cook, Adrian, Wiesner, Lubbe, Mulenga, Veronica, Kityo, Cissy, Kekitiinwa, Addy, Walker, A. Sarah, Owen, Andrew, Gibb, Diana M., Burger, David, McIlleron, Helen, and Denti, Paolo
- Subjects
NEVIRAPINE ,GENETIC polymorphisms ,PHARMACOKINETICS ,DEMOGRAPHIC research ,CHILDREN ,BACTERIA ,BLOOD plasma ,CIRCADIAN rhythms ,LONGITUDINAL method ,OXIDOREDUCTASES ,PSYCHOLOGICAL tests ,RESEARCH funding ,ANTI-HIV agents ,GENOTYPES - Abstract
Objectives: To characterize the effects of CYP2B6 polymorphisms, diurnal variation and demographic factors on nevirapine pharmacokinetics in African children.Methods: Non-linear mixed-effects modelling conducted in NONMEM 7.3 described nevirapine plasma concentration-time data from 414 children aged 0.3-15 years.Results: Nevirapine pharmacokinetics was best described using a one-compartment disposition model with elimination through a well-stirred liver model accounting for a first-pass effect and transit-compartment absorption. Intrinsic clearance was affected by diurnal variation (characterized using a cosine function with peak amplitude 29% at 12 noon) and CYP2B6 metabolizer status [extensive metabolizer (EM) 516GG|983TT, reference; intermediate metabolizer (IM) 516GT|983TT or 516GG|983TC, 17% lower; slow metabolizer (SM) 516TT|983TT or 516GT|983TC, 50% lower; ultra-slow metabolizer (USM) 516GG|983CC, 68% lower]. Age was found to affect pre-hepatic bioavailability: 31.7% lower at birth and increasing exponentially. Median (90% CI) evening Cmin values in the different metabolizer groups were 5.01 (3.01-7.47), 6.55 (3.65-13.32), 11.59 (5.44-22.71) and 12.32 (12.32-27.25) mg/L, respectively. Evening Cmin values were <3 mg/L in 43% of EM weighing <6 kg and 26% of IM weighing <6 kg, while 73% of SM and 88% of USM in all weight-bands had evening Cmin values >8 mg/L. Cmin was not markedly affected by administration time, but was altered by unequal splitting of the daily dose.Conclusions: Diurnal variation does not greatly affect nevirapine exposure. However, when daily doses cannot be split equally, the larger dose should be given in the morning. To achieve homogeneous exposures, nevirapine doses for SM and USM should be reduced by 50%, and children weighing <6 kg with EM or IM metabolizer status should receive the same dose as children weighing 6-10 kg. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
30. Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.
- Author
-
Sandkovsky, Uriel, Podany, Anthony T., Fletcher, Courtney V., Owen, Andrew, Felton-Coleman, Angela, Winchester, Lee C., Robertson, Kevin, and Swindells, Susan
- Subjects
EFAVIRENZ ,PHARMACOKINETICS ,PHARMACODYNAMICS ,GENETIC polymorphisms ,HIV-positive persons ,BACTERIA ,HIV infection complications ,AIDS dementia complex ,ANXIETY ,BLOOD plasma ,MENTAL depression ,HETEROCYCLIC compounds ,NEUROPSYCHOLOGICAL tests ,OXIDOREDUCTASES ,PHARMACOGENOMICS ,RESEARCH funding ,CROSS-sectional method ,ANTI-HIV agents ,REVERSE transcriptase inhibitors - Abstract
Background: Pharmacokinetics (PK) and pharmacodynamics of efavirenz and its 8-hydroxy metabolite (8-OH-efavirenz) have not been robustly evaluated in older HIV-infected persons.Objectives: We investigated relationships between neuropsychological (NP) performance and efavirenz and 8-OH-efavirenz PK in HIV-infected individuals >50 years of age.Methods: A cross-sectional study of HIV-infected adults on an efavirenz-containing regimen. The 12 and 18 h post-dose plasma efavirenz and 8-OH-efavirenz were quantified. CYP2B6 polymorphisms were investigated. Participants underwent neuropsychological tests; surveys were used for depression, sleep quality and anxiety. We investigated potential correlations of efavirenz and 8-OH-efavirenz plasma concentrations with NP performance, sleep, depression, anxiety and CYP2B6 polymorphisms.Results: Thirty participants (24 men and 6 women) with mean age 57 years (range 50-68). Plasma efavirenz concentrations did not correlate with NP performance; however, higher plasma 8-OH-efavirenz correlated with better learning (P = 0.002), language (P = 0.002) and total NP z-scores (P = 0.003). No correlation was seen for efavirenz or 8-OH-efavirenz with sleep, anxiety or depression. Median 12 and 18 h efavirenz plasma concentrations were 1967 ng/mL (IQR 1476-2394) and 1676 ng/mL (IQR 1120-2062), respectively. Median 12 and 18 h 8-OH-efavirenz plasma concentrations were 378 ng/mL (IQR 223-589) and 384 ng/mL (IQR 216-621), respectively. CYP2B6 G516T was associated with significantly higher plasma efavirenz at 12 and 18 h (P = 0.02) but not worse NP function.Conclusions: Better neurocognitive functioning was associated with higher 8-OH-efavirenz but not efavirenz plasma concentrations. No correlation was observed with sleep or depression. These findings point to a need for greater understanding of the metabolic profile of efavirenz and 8-OH-efavirenz in plasma and the CNS and relationships with antiviral effect and neurotoxicity. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
31. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
- Author
-
Elliot, Emilie, Amara, Alieu, Jackson, Akil, Moyle, Graeme, Else, Laura, Khoo, Saye, Back, David, Owen, Andrew, and Boffito, Marta
- Subjects
DRUG efficacy ,PHARMACOKINETICS ,DRUG dosage ,DOSAGE forms of drugs ,DRUG resistance in bacteria ,COMPARATIVE studies ,DRUG monitoring ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,QUINOLONE antibacterial agents ,RESEARCH ,RESEARCH funding ,TIME ,EVALUATION research ,ANTI-HIV agents ,IMPACT of Event Scale - Abstract
Objectives: To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation.Methods: Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day wash-out period, and then received elvitegravir/cobicistat as part of Stribild(®) (245 mg of tenofovir, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days. Serial pharmacokinetic (PK) sampling occurred prior to the final dose of each course and at regular intervals for up to 216 h (10 days) after drug cessation. Concentrations were determined by LC-MS/MS, and PK parameters were illustrated as geometric mean and 90% CI.Results: Seventeen volunteers completed the study. For dolutegravir, plasma terminal elimination t1/2 to the last measurable concentration (within 216 h) was longer than its t1/2 within the dosing interval (0-24 h): 14.3 h (12.9-15.7 h) versus 23.1 h (19.7-26.6 h); conversely, the terminal elimination t1/2 for elvitegravir was lower than its t1/2 within the dosing interval (0-24 h): 10.8 h (9.7-13.0 h) versus 5.2 h (4.7-6.1 h). Dolutegravir concentrations were above the protein-adjusted (PA) IC90 (64 ng/mL) in 100% of subjects after 36 and 48 h and in 94% after 60 and 72 h. All subjects had detectable dolutegravir concentrations at 96 h, a mean of 23.5% above the IC90. Elvitegravir concentrations were above the PA IC95 (45 ng/mL) in 100% of subjects at 24 h, 65% at 36 h but 0% after 48 h.Conclusions: Our data show marked differences in the elimination rates of dolutegravir and elvitegravir following treatment interruption, which is likely to impact the extent to which drug doses can be delayed or missed. They suggest that clinical differences may emerge in patients who have suboptimal adherence. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
32. Class-specific relative genetic contribution for key antiretroviral drugs.
- Author
-
Siccardi, Marco, Olagunju, Adeniyi, Simiele, Marco, D'Avolio, Antonio, Calcagno, Andrea, Di Perri, Giovanni, Bonora, Stefano, and Owen, Andrew
- Subjects
ANTIRETROVIRAL agents ,PHARMACOKINETICS ,RALTEGRAVIR ,ATAZANAVIR ,BLOOD plasma ,PHARMACOGENOMICS ,RESEARCH funding ,RETROSPECTIVE studies - Abstract
Objectives: Antiretroviral pharmacokinetics is defined by numerous factors affecting absorption, distribution, metabolism and elimination. Biological processes underpinning drug distribution are only partially characterized and multiple genetic factors generate cumulative or antagonistic interactions, which complicates the implementation of pharmacogenetic markers. The aim of this study was to assess the degree to which heredity influences pharmacokinetics through the quantification of the relative genetic contribution (rGC) for key antiretrovirals.Methods: A total of 407 patients receiving lopinavir/ritonavir, atazanavir/ritonavir, atazanavir, efavirenz, nevirapine, etravirine, maraviroc, tenofovir or raltegravir were included. Intra-patient variability (SDw) and inter-patient (SDb) variability were measured in patients with plasma concentrations available from more than two visits. The rGC was calculated using the following equation: 1 - (1 / F) where F = SDb(2) / SDw(2).Results: Mean (95% CI) rGC was calculated to be 0.81 (0.72-0.88) for efavirenz, 0.74 (0.61-0.84) for nevirapine, 0.67 (0.49-0.78) for etravirine, 0.65 (0.41-0.79) for tenofovir, 0.59 (0.38-0.74) for atazanavir, 0.47 (0.27-0.60) for atazanavir/ritonavir, 0.36 (0.01-0.48) for maraviroc, 0.15 (0.01-0.44) for lopinavir/ritonavir and 0 (0-0.33) for raltegravir.Conclusions: The rank order for genetic contribution to variability in plasma concentrations for the study drugs was efavirenz > nevirapine > etravirine > tenofovir > atazanavir > atazanavir/ritonavir > maraviroc > lopinavir/ritonavir > raltegravir, indicating that class-specific differences exist. The rGC strategy represents a useful tool to rationalize future investigations as drugs with higher rGC scores may represent better candidates for pharmacogenetic-pharmacokinetic studies. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
33. Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.
- Author
-
Olagunju, Adeniyi, Amara, Alieu, Waitt, Catriona, Else, Laura, Penchala, Sujan D., Bolaji, Oluseye, Soyinka, Julius, Siccardi, Marco, Back, David, Owen, Andrew, and Khoo, Saye
- Subjects
BLOOD plasma ,BREAST milk ,DRUG monitoring ,DRUG stability ,LIQUID chromatography ,MASS spectrometry ,RESEARCH evaluation ,RESEARCH funding ,NEVIRAPINE ,ANTI-HIV agents - Abstract
Objectives: The validation and clinical application of an LC-MS/MS method for the quantification of nevirapine in dried blood spots (DBS) and dried breast-milk spots (DBMS) are presented.Methods: DBS and DBMS were prepared from 50 and 30 μL of nevirapine-spiked whole blood and human breast milk, respectively. Chromatographic separation was achieved on a reverse-phase C18 column with 0.1% formic acid in water/acetonitrile using a solvent gradient programme at a flow rate of 400 μL/min, and detection was by a TSQ Quantum Access triple quadrupole mass spectrometer. The clinical application was evaluated in HIV-positive nursing mothers and their breastfed infants.Results: The assay was validated over the concentration range 50-10,000 ng/mL. Accuracy ranged from 93.3% to 113.4% and precision ranged from 1.9% to 12.0%. The mean (percentage coefficient of variation) recovery of nevirapine from DBS and DBMS was ≥ 70.7% (≤ 8.2) and the matrix effect was ≤ 1.04 (≤ 6.1). Nevirapine was stable in DBS and DBMS for ≥ 15 months at room temperature and -80°C. Mean (SD) AUC0-12, Cmax and Cmin in maternal plasma versus breast milk were 57,808 ng · h/mL (24,315) versus 55,817 ng · h/mL (22,368), 6140 ng/mL (2605) versus 5231 ng/mL (2215) and 4334 ng/mL (1880) versus 4342 ng/mL (2245), respectively. The milk-to-plasma concentration ratio over the dosing interval was 0.94 (0.15). Infant plasma concentrations 2 and 8 h after maternal dosing were 580.6 ng/mL (464.7-1607) and 584.1 ng/mL (381.5-1570), respectively.Conclusions: These methods further extend opportunities for conducting clinical pharmacokinetic studies in nursing mother-infant pairs, especially in resource-limited settings. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
34. Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study.
- Author
-
Olagunju, Adeniyi, Bolaji, Oluseye, Amara, Alieu, Waitt, Catriona, Else, Laura, Adejuyigbe, Ebunoluwa, Siccardi, Marco, Back, David, Khoo, Saye, and Owen, Andrew
- Subjects
BREAST milk ,PHARMACOKINETICS ,EFAVIRENZ ,INFANT health ,SINGLE nucleotide polymorphisms ,ANTIRETROVIRAL agents ,BREASTFEEDING ,THERAPEUTICS - Abstract
Background. The antiretroviral drug efavirenz is widely used during breastfeeding. Evaluating its safety requires an understanding of its breast milk pharmacokinetics, level of breastfed infants' exposure, and potential influence of polymorphisms in drug disposition genes. Methods. For this observational study, we investigated plasma and breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in human immunodeficiency virus positive nursing mothers and their breastfed infants. We also evaluated potential variability due to genetic polymorphisms in CYP2B6, NR1I3, CYP2A6, ABCB1, ABCB5, and ABCG2. Results. CYP2B6 516G>T was independently associated with efavirenz concentrations in maternal plasma, breast milk, and infant plasma (n = 134). When stratified based on CYP2B6 516G>T (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breast milk differed significantly between patient groups. The median time-averaged milk-to-plasma concentration ratio was 1.10 (range: 0.57-1.71). The estimated maximum infant efavirenz dose from breast milk was 809 µg/kg/day (215-2760) and pediatric dose weight-adjusted exposure index was 4.05% (1.08-13.8). Infant plasma concentrations did not change significantly during the dosing interval, 157 ng/mL (28.6-1360) in pooled analysis and 315 ng/mL (108-1360) in CYP2B6 516TT group. Infant plasma concentrations were highest up to 8 days of age at 1590 ng/mL (190-4631) and decreased by about 90% in the age stratum day 9 to 3 months. No efavirenz related toxicity was reported. Conclusions. Most breastfed infants are exposed to <10% of the weight-adjusted therapeutic pediatric dose, the safety threshold for exposure to maternal drugs from breast milk. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial.
- Author
-
Winston, Alan, Amin, Janaki, Clarke, Amanda, Else, Laura, Amara, Alieu, Owen, Andrew, Barber, Tristan, Jessen, Heiko, Avinghsanon, Anchalee, Chetchotisakd, Ploenchan, Saye Khoo, Cooper, David A., Emery, Sean, and Puls, Rebekah
- Subjects
CEREBROSPINAL fluid examination ,EFAVIRENZ ,METABOLITES ,HIV infections ,THERAPEUTICS ,VIRAL replication ,ANTIRETROVIRAL agents ,CYTOCHROME P-450 ,PHARMACOKINETICS ,PREVENTION - Abstract
Background. The optimal penetration of antiretroviral agents into the central nervous system may be a balance between providing adequate drug exposure to inhibit human immunodeficiency virus (HIV) replication while avoiding concentrations associated with neuronal toxicities. Methods. Cerebrospinal fluid (CSF) exposure of efavirenz and the metabolites 7-hydroxy (7OH) and 8-hydroxy (8OH) efavirenz were assessed after at least 12 weeks of therapy in HIV-infected subjects randomized to commence antiretroviral regimens containing efavirenz at either 400 mg or 600 mg once daily. Results. Of 28 subjects (14 and 14 on efavirenz 400 mg and 600 mg, respectively), CSF HIV RNA was undetectable in all. Geometric mean CSF efavirenz, 7OH-, and 8OH-efavirenz concentrations (with 90% confidence intervals [CIs]) for the 400-mg and 600-mg dosing groups were 16.5 (13-21) and 19.5 (15-25) ng/mL; 0.6 (.4-.9) and 0.6 (.4-1) ng/mL; and 5.1 (4.0-6.4) and 3.1 (2.1-4.4) ng/mL, respectively. Efavirenz concentration in CSF was >0.51 ng/mL (proposed CSF 50% maximal inhibitory concentration for wild-type virus) in all subjects, and 8OH-efavirenz concentration in CSF was >3.3 ng/mL (a proposed toxicity threshold) in 11 of 14 and 7 of 14 subjects randomized to the 400 mg and 600 mg doses of efavirenz, respectively. Whereas CSF efavirenz concentration was significantly associated with plasma concentration (P < .001) and cytochrome P450 2B6 genotype (CSF efavirenz GG to GT/TT geometric mean ratio, 0.56 [90% CI, .42-.74]), CSF 8OH-efavirenz concentration was not (P = .242 for association and CSF 8OH-efavirenz GG to GT/TT geometric mean ratio, 1.52 [90% CI, .97- 2.36]). Conclusions. With both doses of efavirenz studied, CSF concentrations were considered adequate to inhibit HIV replication, although concentrations of 8OH-efavirenz were greater than those reportedly associated with neuronal toxicity. CSF exposure of 8OH-efavirenz was not dependent on plasma exposure and, as we postulate, may be subject to saturable pharmacokinetic effects. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.
- Author
-
Olagunju, Adeniyi, Bolaji, Oluseye O, Amara, Alieu, Waitt, Catriona, Else, Laura, Soyinka, Julius, Adeagbo, Babatunde, Adejuyigbe, Ebunoluwa, Siccardi, Marco, Back, David, Owen, Andrew, and Khoo, Saye
- Abstract
Objectives: This manuscript describes the development, validation and clinical application of a novel method for the quantification of the antiretroviral drug efavirenz in dried breast milk spots using LC-MS.Methods: Dried breast milk spots were prepared by spotting 30 μL of human breast milk on each circle of Whatman 903 Protein Saver cards. Chromatographic separation was achieved on a reverse-phase C18 column with 1 mM ammonium acetate in water/acetonitrile using a solvent gradient at a flow rate of 400 μL/min and detection was by TSQ Quantum Access triple quadrupole mass spectrometer equipped with a heated electrospray ionization source. The method was applied to characterize the breast milk pharmacokinetic profile of efavirenz in HIV-positive nursing mothers receiving regimens containing 600 mg of efavirenz once daily.Results: The assay was validated over the concentration range 50-7500 ng/mL. Accuracy ranged between 95.2% and 102.5% and precision ranged between 1.05% and 9.53%. The average recovery of efavirenz from dried breast milk spots was 106.4% and the matrix effect was 8.14%. Stability of efavirenz in dried breast milk spots and processed samples at room temperature, -40°C and -80°C was demonstrated. In the pharmacokinetic study, the mean (SD) AUC0-24, Cmax and Cmin of efavirenz in breast milk were 59,620 ng·h/mL (17,440), 4527 ng/mL (1767) and 1261 ng/mL (755.9), respectively. The mean (range) milk-to-plasma concentration ratio over the dosing interval was 0.78 (0.57-1.26).Conclusions: The dried breast milk spot method is simple, robust, accurate and precise, and can be used in settings with limited resources. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
37. A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication.
- Author
-
Moss, Darren M., Curley, Paul, Shone, Alison, Siccardi, Marco, and Owen, Andrew
- Subjects
CLINICAL trials ,RALTEGRAVIR ,LOPINAVIR-ritonavir ,DRUG metabolism ,DRUG residues in the body - Abstract
Objectives Recent clinical data have suggested high raltegravir concentrations in gut tissue after oral administration, with implications for treatment and prevention. We have used in silico, in vitro, ex vivo and in vivo models to further investigate the accumulation of raltegravir in gut tissue. Methods Affinity of raltegravir for gut tissue was assessed in silico (Poulin–Theil method), in vitro (Caco-2 accumulation) and ex vivo (rat intestine) and compared with the lipophilic drug lopinavir. Finally, raltegravir concentrations in plasma, gut contents, small intestine and large intestine were determined after oral dosing to Wistar rats 1 and 4 h post-dose. Samples were analysed using LC-MS/MS and scintillation counting. Results Gut tissue accumulation of raltegravir was less than for lopinavir in silico, in vitro and ex vivo (P < 0.05). After oral administration to rats, raltegravir concentrations 4 h post-dose were lower in plasma (0.05 μM) compared with small intestine (0.47 μM, P = 0.06) and large intestine (1.36 μM, P < 0.05). However, raltegravir concentrations in the contents of both small intestine (4.0 μM) and large intestine (40.6 μM) were also high. Conclusions In silico, in vitro and ex vivo data suggest low raltegravir accumulation in intestinal tissue. In contrast, in vivo animal data suggest raltegravir concentrates in intestinal tissue even when plasma concentrations are minimal. However, high raltegravir concentrations in gut contents are the likely driving factor behind this observation, rather than blood-to-tissue drug distribution. The methods described can be combined with clinical investigations to provide a complete strategy for selection of drugs with high gut accumulation. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
38. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
- Author
-
Sarfo, Fred S., Zhang, Yuan, Egan, Deirdre, Tetteh, Lambert A., Phillips, Richard, Bedu-Addo, George, Sarfo, Maame Anima, Khoo, Saye, Owen, Andrew, and Chadwick, David R.
- Subjects
EFAVIRENZ ,ANTIRETROVIRAL agents ,PHARMACODYNAMICS ,NUCLEOTIDE sequence ,GENETIC polymorphism research - Abstract
Objectives Efavirenz is widely used in first-line antiretroviral therapy in sub-Saharan Africa. However, exposure to efavirenz shows marked interindividual variability that is genetically mediated with potential for important pharmacodynamic consequences. The aims of this study were to assess the frequencies of CYP2B6, CYP2A6, UGT2B7 and CAR single nucleotide polymorphisms (SNPs) and their impact on plasma efavirenz concentration and clinical/immunological responses in Ghanaian patients. Methods Genomic DNA from 800 HIV-infected patients was genotyped for selected SNPs by real-time PCR-based allelic discrimination. Mid-dose plasma efavirenz concentrations were measured for 521 patients using HPLC with UV detection. Clinical outcomes in 299 patients on efavirenz were retrospectively assessed. Univariate and multivariate linear regression were performed using best subset selection. Time-to-event outcomes were analysed using a Cox proportional hazards regression model. Results The variant allele frequencies for CYP2B6 516G>T (rs3745274), CYP2B6 983T>C (rs28399499), CYP2A6 −48T>G (CYP2B6*9B; rs28399433), UGT2B7 802C>T (UGT2B7*2; rs7439366), UGT2B7 735A>G (UGT2B7*1c; rs28365062) and CAR 540C>T (rs2307424) were 48%, 4%, 3%, 23%, 15% and 7%, respectively. CYP2B6 516G>T, CYP2B6 983T>C and CYP2A6 −48T>G were associated with significantly elevated efavirenz concentrations. A trend towards association between plasma efavirenz concentration and CAR 540C>T was observed. CYP2B6 516G homozygosity was associated with immunological failure [adjusted hazards ratio compared with T homozygosity, 1.70 (1.04–2.76); P = 0.03]. Conclusions CYP2B6 and CYP2A6 SNPs were associated with higher plasma efavirenz concentrations due to reduction in major and minor phase I routes of elimination, respectively. Further prospective studies are needed to validate the pharmacodynamic correlates of these polymorphisms in this population. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
39. Predicting intestinal absorption of raltegravir using a population-based ADME simulation.
- Author
-
Moss, Darren M., Siccardi, Marco, Back, David J., and Owen, Andrew
- Subjects
INTESTINAL absorption ,ABSORPTION (Physiology) ,RALTEGRAVIR ,HIV integrase inhibitors ,HIV - Abstract
Objectives Raltegravir pharmacokinetics (PK) show high intra- and inter-patient variability and are also influenced by co-administered substances that alter the gastrointestinal tract environment, such as pH-altering or metal-containing agents. The aim of this investigation was to develop a population-based absorption, distribution, metabolism and excretion (ADME) model to investigate the effects of gastrointestinal pH and ingested magnesium on raltegravir PK. Methods In vitro data describing the disposition of raltegravir were obtained from literature sources or generated by standard methods. Raltegravir (400 mg single dose) PK were simulated in healthy volunteers (50 subjects per group, 20–50 years old, 0.5 proportion female subjects) over a 12 h period. Results Simulated raltegravir PK correlated well with data from clinical trials, with a mean deviation in Cmax, AUC0-12 and Ctrough of <20%. Solubility of raltegravir in the gastrointestinal tract was increased at higher luminal pH. Increased intestinal pH and transit time both correlated with higher raltegravir absorption (P < 0.001). Magnesium ingestion reduced raltegravir exposure in simulated subjects, with mean Ctrough reduced by 32% (P < 0.001). Conclusions The in vitro–in vivo extrapolation model developed in this study predicted raltegravir PK in virtual individuals with different gastrointestinal pH profiles. The main PK variables were predicted with good accuracy compared with reference data, and both luminal pH and magnesium were able to influence drug absorption. This modelling system provides a tool for investigating the absorption of other drugs, including HIV integrase inhibitors currently in development, which have also shown interactions with food and metal-containing products. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
40. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
- Author
-
Okoli, Chinyere, Siccardi, Marco, Thomas-William, Sathish, Dufty, Ngozi, Khonyongwa, Kirstin, Ainsworth, Jonathan, Watson, John, Cook, Roseanne, Gandhi, Kate, Hickinbottom, Geraldine, Owen, Andrew, and Taylor, Stephen
- Subjects
PHARMACOKINETICS ,MARAVIROC (Drug) ,DARUNAVIR ,TENOFOVIR ,EMTRICITABINE ,EMTRICITABINE-tenofovir - Abstract
Objectives To describe the pharmacokinetics of maraviroc when dosed at 150 or 300 mg once daily with 800/100 mg of darunavir/ritonavir. Methods A retrospective case-note review of HIV-infected adults taking maraviroc was conducted. Patients on a maraviroc-based regimen for a minimum of 5 weeks were grouped as receiving: (i) 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine; (ii) 300 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily; and (iii) 150 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily. Ctrough and Cpeak data were collected at 2, 12 or 24 h post-dose. Results Sixty-six patients were included, providing 115 samples. The median (IQR) Cpeak was 378 (350–640) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n = 9), 728 (378–935) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n = 29) and 364 (104–624) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n = 2; P = 0.24). The median (IQR) Ctrough was 46 (33–61) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n = 12), 70 (49–97) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n = 34) and 43 (35–55) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n = 17; P = 0.001). The maraviroc Ctrough in black patients (n = 34) was 61 (45–110) ng/mL and in white patients (n = 29) it was 49 (42–70) ng/mL (P = 0.04). The Cpeak in black patients (n = 20) was 800 (397–1060) ng/mL versus 387 (336–723) ng/mL in white patients (n = 20; P = 0.02). Conclusions Once daily coadministration of 300 mg of maraviroc with 800/100 mg of darunavir/ritonavir was well tolerated and had favourable pharmacokinetics when compared with 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine. A 24% higher Ctrough and 107% higher Cpeak was seen in black patients compared with white patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
41. Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.
- Author
-
Taylor, Stephen, Jayasuriya, Ashini, Fisher, Martin, Allan, Sris, Wilkins, Ed, Gilleran, Gerry, Heald, Lisa, Fidler, Sarah, Owen, Andrew, Back, David, and Smit, Erasmus
- Subjects
ANTIRETROVIRAL agents ,LOPINAVIR-ritonavir ,EFAVIRENZ-emtricitabine-tenofovir (Drug) ,NUCLEOTIDES ,DRUG resistance - Abstract
Objectives We designed two different studies to evaluate two different combination antiretroviral therapy (cART) stopping strategies namely a ‘staggered stop’ approach (STOP 1 study) and a ‘protected stop’ approach (STOP 2 study) to find the best ‘universal stop’ strategy. Patients and methods Patients who stopped cART for any reason were recruited. In STOP 1, 10 patients on efavirenz continued dual nucleos(t)ide reverse transcriptase inhibitors (NRTIs) for 1 week after discontinuing efavirenz. Efavirenz concentrations were measured weekly for up to 3 weeks. In STOP 2, 20 patients stopped their cART and replaced it with two tablets of lopinavir/ritonavir (Kaletra) (100/50 mg) twice daily for 4 weeks. Lopinavir, efavirenz, nevirapine and tenofovir concentrations were measured weekly for up to 4 weeks. Virological and resistance testing were performed. Results In STOP 1 five patients still had efavirenz present (median t1/2 = 148.4 h) 3 weeks after stopping. In STOP 2, 15/20 patients had a viral load (VL) of <40 copies/mL and 3/20 patients had a reduction in VL by 4 weeks. Six patients opted not to stop lopinavir/ritonavir and still had <40 copies/mL at week 8. Week 1–4 median trough lopinavir concentrations were well above the EC95. Six patients still had detectable concentrations of original cART persisting for >1 week after stopping. No patients developed new resistance mutations. Conclusions Plasma efavirenz concentrations can persist up to 3 weeks after patients stop efavirenz-containing regimens. This suggests a strategy of stopping efavirenz only 1 week before NRTIs may not be long enough for some individuals. The use of lopinavir/ritonavir monotherapy for a 4 week period may be an alternative pharmacologically and virologically effective universal stopping strategy which warrants further investigation. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
42. Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy.
- Author
-
Doyle, Tomas, Smith, Colette, Vitiello, Paola, Cambiano, Valentina, Johnson, Margaret, Owen, Andrew, Phillips, Andrew N., and Geretti, Anna Maria
- Subjects
HIV infections ,THERAPEUTICS ,ANTIRETROVIRAL agents ,BLOOD plasma ,VIRAL load ,BIOLOGICAL assay ,RNA ,HEALTH outcome assessment - Abstract
Background. Plasma human immunodeficiency virus type 1 (HIV-1) RNA suppression <50 copies/mL is regarded as the optimal outcome of highly active antiretroviral therapy (HAART). Current viral load (VL) assays show increased sensitivity, but the significance of RNA detection <50 copies/mL is unclear. Methods. This study investigated the virologic outcomes of 1247 patients with VL <50 copies/mL at an arbitrary time point during HAART (= T0), according to whether the actual, unreported
T0 VL was 40-49 copies/mL, RNA detected <40 copies/mL (RNA1), or RNA not detected (RNA2), as measured by the Abbott Real Time assay. Predictors of rebound >50 and >400 copies/mL over 12 months following T0 were analyzed with Cox proportional hazards models incorporating theT0 VL and demographic and clinical data. Results. Rebound rates >50 copies/mL were 34.2% for T0VL 40-49 copies/mL, 11.3% for RNA+ , and 4.0% for RNA- ; rebound rates >400 copies/mL were 13.0%, 3.8%, and 1.2%, respectively. The adjusted hazard ratios for rebound >50 copies/mL were 4.67 (95% confidence interval, 2.91-7.47; P < .0001) and 1.97 (1.25-3.11; P < .0001) withTO VL 40-49 copies/mL and RNA+ , respectively, relative to RNA- , and 6.91 (2.90-16.47; P, .0001) and 2.88 (1.24-6.69; P < .0001), respectively, for rebound >400 copies/mL. The association was independent of adherence levels. Conclusions. In treated patients monitored by RealTime, a VL of 40-49 copies/mL and, to a lesser extent, RNA detection <40 copies/mL predict rebound >50 and >400 copies/mL independently of other recognized determinants. The goal of HAART may need to be revised to a lower cutoff than 50 copies/mL. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
43. Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction.
- Author
-
Pushpakom, Sudeep P., Liptrott, Neill J., Rodríguez-Nóvoa, Sonia, Labarga, Pablo, Soriano, Vincent, Albalater, Marta, Hopper-Borge, Elizabeth, Bonora, Stefano, Di Perri, Giovanni, Back, David J., Khoo, Saye, Pirmohamed, Munir, and Owen, Andrew
- Abstract
Background. Tenofovir (TFV) causes kidney tubular dysfunction (KTD) in some patients, but the mechanism is poorly understood. Genetic variants in TFV transporters are implicated; we explored whether ABCC10 transports TFV and whether ABCC10 single-nucleotide polymorphisms (SNPs) are associated with KTD.Methods. TFV accumulation was assessed in parental and ABCC10-transfected HEK293 cells (HEK293-ABCC10), CD4+ cells and monocyte-derived macrophages (MDMs). Substrate specificity was confirmed by cepharanthine (ABCC10 inhibitor) and small interfering RNA (siRNA) studies. Fourteen SNPs in ABCC10 were genotyped in human immunodeficiency virus–positive patients with KTD (n = 19) or without KTD (controls; n = 96). SNP and haplotype analysis was performed using Haploview.Results. TFV accumulation was significantly lower in HEK293-ABCC10 cell lines than in parental HEK293 cells (35% lower; P = .02); this was reversed by cepharanthine. siRNA knockdown of ABCC10 resulted in increased accumulation of TFV in CD4+ cells (18%; P = .04) and MDMs (25%; P = .04). Two ABCC10 SNPs (rs9349256: odds ratio [OR], 2.3; P = .02; rs2125739, OR, 2.0; P = .05) and their haplotype (OR, 2.1; P = .05) were significantly associated with KTD. rs9349256 was associated with urine phosphorus wasting (P = .02) and β2 microglobulinuria (P = .04).Conclusions. TFV is a substrate for ABCC10, and genetic variability within the ABCC10 gene may influence TFV renal tubular transport and contribute to the development of KTD. These results need to be replicated in other cohorts. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
44. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
- Author
-
Schipani, Alessandro, Wyen, Christoph, Mahungu, Tabitha, Hendra, Heidy, Egan, Deirdre, Siccardi, Marco, Davies, Gerry, Saye Khoo, Fätkenheuer, Gerd, Youle, Michael, Rockstroh, Jürgen, Brockmeyer, Norbert H., Johnson, Margaret A., Owen, Andrew, and Back, David J.
- Subjects
NEVIRAPINE ,PHARMACOKINETICS ,PHARMACOGENOMICS ,HIV infections ,ANTIRETROVIRAL agents - Abstract
Background Nevirapine is metabolized by CYP2B6 and polymorphisms within the CYP2B6 gene partly explain inter-patient variability in pharmacokinetics. The aim of this study was to model the complex relationship between nevirapine exposure, weight and genetics (based on combined analysis of CYP2B6 516G > T and 983T > C single nucleotide polymorphisms). Methods Non-linear mixed-effects modelling was used to estimate pharmacokinetic parameters from 275 patients. Simulations of the nevirapine concentration profile were performed with dosing regimens of 200 mg twice daily and 400 mg once daily for individuals with body weights of 50, 70 and 90 kg in combination with CYP2B6 genetic variation. Results A one-compartment model with first-order absorption best described the data. Population clearance was 3.5 L/h with inter-patient variability of 24.6%. 516T homozygosity and 983C heterozygosity were associated with 37% and 40% lower clearance, respectively. Body weight was the only significant demographic factor influencing clearance, which increased by 5% for every 10 kg increase. For individuals with higher body weight, once-daily nevirapine was associated with a greater risk of sub-therapeutic drug exposure than a twice-daily regimen. This risk was offset in individuals who were 516T homozygous or 983C heterozygous in which drug exposure was optimal for > 95% of patients with body weight of ≤70 kg. Conclusions The data suggest that a 400 mg once-daily dose could be implemented in accordance with CYP2B6 polymorphism and body weight. However, the use of nevirapine once daily (immediate release; off-label) in the absence of therapeutic drug monitoring is not recommended due to the risk of inadequate exposure to nevirapine in a high proportion of patients. There are different considerations for the extended-release formulation (nevirapine XR) that demonstrate minimal peak-to-trough fluctuations in plasma nevirapine levels. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
45. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
- Author
-
Carr, Daniel F., la Porte, Charles J. L., Pirmohamed, Munir, Owen, Andrew, and Cortes, Claudia P.
- Subjects
MEDICAL research ,ANTIRETROVIRAL agents ,PHARMACOKINETICS ,GENETIC polymorphisms ,LIQUID chromatography - Abstract
Objectives: Efavirenz is extensively metabolized by CYP2B6, and associations between CYP2B6 polymorphisms and plasma efavirenz exposure have been reported. The objective of this study was to investigate CYP2B6 haplotype structure and functional consequences in a Latin American population. Patients and methods: Two hundred and nineteen patients were recruited at Fundacio'n Arriara'n, Chile, between September and December 2008. Plasma efavirenz concentrations were determined using liquid chromatography with mass spectrometry. Genotyping for 30 single nucleotide polymorphisms (SNPs) with a minor allele frequency of >0.05 in the HapMap CEU population at intervals of ~1 kb across the CYP2B6 locus was conducted using Sequenom iPLEX MALDI-TOF. Results: Thirteen SNPs passed quality control and, of these, statistically significant associations (P<0.001) with plasma efavirenz concentrations were observed for 11. Pairwise tagging SNP analysis (R²>.0.8) identified 3 SNPs (rs10403955, rs2279345 and rs8192719) representative of the 11 associated SNPs. A composite genetic model of these three alleles was constructed, and an association between carriers of four to six of these alleles and the risk of efavirenz plasma concentrations >4 µg/mL was identified with an odds ratio of 48.1 (95% confidence interval: 13.5-207.7). This represents a positive predictive value of 80.9% and a negative predictive value of 91.8%, with sensitivity of 57.9% and specificity of 97.2%. Conclusions: A composite genetic model of CYP2B6 SNPs in a Chilean HIV-positive cohort may have value in predicting concentrations of efavirenz associated with a higher likelihood of CNS toxicity. Further investigation of the functional basis of these associations is now required. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
46. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.
- Author
-
Janneh, Omar, Chandler, Becky, Hartkoorn, Ruben, Wai San Kwan, Jenkinson, Claire, Evans, Sorcha, Back, David J., Owen, Andrew, and Khoo, Saye H.
- Subjects
GLYCOPROTEINS ,T cells ,LYMPHOCYTES ,B cells ,ANTIRETROVIRAL agents ,MULTIDRUG resistance - Abstract
Background: Interaction of antiretrovirals with drug transporters such as P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), breast cancer resistance protein (BCRP) and solute carrier organic anion transporter (SLCO) may influence the emergence of viral mutants by altering intracellular drug concentrations. Here we characterize the effect of transporter expression in a variety of cell types such as control CEM, CEMVBL (P-gp-overexpressing), CEME1000 (MRP1-overexpressing), MT4, control MDCKII, MDCKIIMDR1 (P-gp-overexpressing) and peripheral blood mononuclear cells (PBMCs) on the uptake of [14C]efavirenz and [3H]nevirapine. We also investigated the lipophilicity of [14C]efavirenz and [3H]nevirapine. [ABSTRACT FROM PUBLISHER]
- Published
- 2009
- Full Text
- View/download PDF
47. Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study.
- Author
-
Rodríguez-Nóvoa, Sonia, Labarga, Pablo, Soriano, Vincent, Egan, Deirdre, Albalater, Marta, Morello, Judit, Cuenca, Lorena, González-Pardo, Gema, Khoo, Saye, Back, David, and Owen, Andrew
- Subjects
PHARMACOGENOMICS ,ANTIRETROVIRAL agents ,GLOMERULAR filtration rate ,KIDNEY glomerulus ,GENETIC polymorphisms ,GENOTYPE-environment interaction ,CHRONIC kidney failure ,THERAPEUTICS ,GENETIC research - Abstract
Background. Tenofovir is one of the most widely used antiretroviral drugs. Tenofovir undergoes renal clearance by a combination of glomerular filtration and active tubular secretion. Although rare, the mechanism by which tenofovir causes renal damage is not well characterized. We have explored the association between kidney tubular dysfunction (KTD) and polymorphisms in genes encoding drug transporters. Methods. All consecutive, human immunodeficiency virus (HIV)-infected patients receiving tenofovir-containing antiretroviral regimens who were seen at a single institution during the first trimester of 2008 were enrolled in the study. KTD was defined by the presence of at least 2 of the following abnormalities: nondiabetic glucosuria, urine phosphate wasting, hyperaminoaciduria, β2-microglobulinuria, and increased fractional excretion of uric acid. Twelve single-nucleotide polymorphisms in the ABCC2, ABCC4, SCL22A6, SLC22A11, and ABCB1 genes were analyzed using TaqMan 5′-nuclease assays. Results. A total of 115 HIV-infected patients were examined, of whom 19 (16.5%) had KTD. The percentage of patients with KTD was higher among those with genotype CC at position -24 of ABCC2 than among those with genotypes CT and TT (24% [16 of 68 patients] vs. 6% [3 of 47 patients]; Pp.020). In a multivariate analysis, older age (odds ratio [OR], 1.1; 95% confidence interval [CI], 1.0-1.2; Pp.024), lower body weight (OR, 0.9; 95% CI, 0.8-0.9; Pp.048), and genotype CC at ABCC2 position -24 (OR, 5; 95% CI, 1.2-21; Pp.027) were independently associated with KTD. Conclusions. Approximately 17% of HIV-infected patients treated with tenofovir had KTD. Homozygosity for the C allele at position -24 of the ABCC2 gene was strongly associated with KTD in this population. This polymorphism may help to identify patients at greater risk for developing tenofovir-associated tubulopathy, and close monitoring of renal function is warranted for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
48. Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396CrT) with Reduced Concentrations of Unboosted Atazanavir.
- Author
-
Siccardi, Marco, D'Avolio, Antonio, Baietto, Lorena, Gibbons, Sara, Sciandra, Mauro, Colucci, Daniela, Bonora, Stefano, Khoo, Saye, Back, David J., Di Perri, Giovanni, and Owen, Andrew
- Subjects
GENETIC polymorphisms ,PREGNANE ,CYTOCHROMES ,NUCLEOTIDES ,LIVER cells ,MASS spectrometry ,CHROMATOGRAPHIC analysis ,MULTIVARIATE analysis ,METABOLISM - Abstract
This study investigated pregnane X receptor polymorphisms in relation to unboosted atazanavir plasma concentrations in 2 cohorts of patients. The polymorphism 63396T→C predicted concentrations below the minimum effective concentration (150 ng/mL) with odds ratios of 18 (P=.008) and 5.13 (P=.02). Prospective studies determining potential clinical usefulness are now warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
49. Comparing outcomes of cataract surgery: challenges and opportunities.
- Author
-
McKee, Martin, Whatling, Justin M., Wilson, John L., and Vallance-Owen, Andrew
- Subjects
CATARACT surgery ,PHACOEMULSIFICATION ,MEDICAL assistance ,PREVENTIVE medicine ,PUBLIC health - Abstract
Background There is an increasing demand for routine assessment of surgical outcomes. However, for assessments to be valid, it is essential to understand the influence of patient characteristics on outcomes. The VF-14 visual function instrument offers a possible means of monitoring outcomes of cataract surgery. This article examines lessons learned in the course of an attempt to do this. [ABSTRACT FROM PUBLISHER]
- Published
- 2005
- Full Text
- View/download PDF
50. Outcome monitoring to facilitate clinical governance; experience from a national programme in the independent sector.
- Author
-
Vallance-Owen, Andrew, Cubbin, Sally, Warren, Virginia, and Matthews, Brian
- Subjects
TREATMENT effectiveness ,QUESTIONNAIRES ,ELECTIVE surgery ,HEALTH surveys ,QUALITY control - Abstract
Background Since 1998 BUPA has used the Short‐Form 36 (SF‐36) questionnaire to monitor changes in health status after adult elective surgery. Over 70 independent hospitals across the United Kingdom have collected data on over 100000 patient episodes. SF‐36 is one of a number of tools that support clinical governance in the sector. Results are reported confidentially, putting the emphasis on supporting a learning culture. [ABSTRACT FROM PUBLISHER]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.